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Summary
Background Treatment of latent yaws is a crucial component of the WHO yaws eradication strategy to prevent relapse 
and the resulting transmission to uninfected children. We assessed the effectiveness of single-dose azithromycin to 
treat patients with latent yaws.
Methods This population-based cohort study included children (age <20 years) living on Lihir Island, Papua New Guinea, 
with high-titre (rapid plasma reagin titre ≥1:8) latent or active yaws, between April, 2013, and May, 2015. Latent yaws 
was defined as lack of suspicious skin lesions or presence of ulcers negative for Treponema pallidum subsp pertenue on 
PCR, and active yaws was defined as ulcers positive for T pertenue on PCR. All children received one oral dose of 
30 mg/kg azithromycin. The primary endpoint was serological cure, defined as a two-dilution decrease in rapid 
plasma reagin titre by 24 months after treatment. Treatment of latent yaws was taken to be non-inferior to that of 
active yaws if the lower limit of the two-sided 95% CI for the difference in rates was higher than or equal to –10%. 
This study is registered with ClinicalTrials.gov, number NCT01955252.
Findings Of 311 participants enrolled, 273 (88%; 165 with latent yaws and 108 with active yaws) completed follow-up. 
The primary endpoint was achieved in 151 (92%) participants with latent yaws and 101 (94%) with active yaws (risk 
difference –2·0%, 95% CI –8·3 to 4·3), meeting the prespecified criteria for non-inferiority. 
Interpretation On the basis of decline in serological titre, oral single-dose azithromycin was effective in participants 
with latent yaws. This finding supports the WHO strategy for the eradication of yaws based on mass administration 
of the entire endemic community irrespective of clinical status.  
Funding Newcrest Mining Limited and ISDIN laboratories. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license. 
Introduction
As with venereal syphilis, patients with yaws can develop 
latent disease that is characterised by seroreactivity 
without other evidence of primary, secondary, or tertiary 
disease. Five to six people are estimated to have latent 
yaws for each case of active disease, and clinical relapse is 
possible for up to 5 years after infection.1,2 Clinical 
diagnosis of yaws has been challenged by the discovery 
that a substantial proportion of skin lesions contain no 
Treponema pallidum subsp pertenue on PCR, but do 
contain DNA sequences specific to Haemophilus ducreyi 
or are caused by as-yet unknown pathogens.3–5 Hence, 
some individuals with reactive yaws serology have skin 
lesions arising from another cause. 
In 2012, a randomised controlled trial in Papua New 
Guinea showed that oral azithromycin was as effective as 
parenteral penicillin in the treatment of active yaws.6 On 
the basis of this finding, WHO adopted a revised strategy 
of treatment with single-dose azithromycin for all 
community members in yaws-endemic areas, irrespective 
of clinical status.7 Treatment of both active and latent 
yaws is crucial for the success of an eradication 
programme, and this strategy allows individuals with 
latent disease to be exposed to curative treatment. 
Despite implementation of pilot programmes in several 
equatorial rural provinces of Africa8 (Aziz A, personal 
communication) and the South Pacific,9–12 and plans to 
expand activities in those regions and worldwide, the 
efficacy of single-dose azithromycin to treat latent yaws 
remains to be esta blished.
The objective of treating people with latent yaws is 
twofold: first, to prevent relapsing episodes and resulting 
transmission to uninfected children1 and, second, to 
prevent progression of the infection to the destructive 
tertiary stage. Late latent syphilis is treated with 
benzathine benzylpenicillin for an extended period of 
time because this antibiotic is active only against dividing 
cells and organisms divide more slowly in the latent 
stage, although the validity of this rationale has not been 
assessed. Thus, single-dose azithromycin might be less 
effective in treating latent infection than active infection 
if the bacterium is less metabolically active.
In this study, we assessed the serological response of 
people with latent yaws to treatment with one dose of 
oral azithromycin. We compared the findings against 
those in people with active yaws.
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Methods
Study design and participants
In the context of the yaws eradication programme of 
Lihir Island, Papua New Guinea,9 we did a prospective 
study that involved all children (age <20 years) with active 
or latent yaws who were residents of the island. Methods 
of the yaws eradication programme, including details of 
treatment and clinical assessment, have been previously 
described.9 Briefly, we administered mass azithro mycin 
treatment in April, 2013, and repeatedly assessed out-
comes in about 16 000 people every 6 months for about 
3·5 years.
Participants attended clinical surveys, during which 
those with ulcers suspected of being due to active yaws 
were assessed for inclusion in the study. People with a 
reactive T pallidum haemagglutination assay (TPHA) and 
rapid plasma reagin (RPR) titre of 1:8 or greater at the 
time of screening were eligible for the study. We excluded 
people with RPR titres of 1:2 or 1:4 because many children 
in high endemic areas have a persistently positive low-
titre RPR results after successful treatment (ie, serofast 
status) that cannot be distinguished from true treponemal 
infection. The criterion for the diagnosis of active yaws 
was ulcers positive for T pertenue on PCR, and for the 
diagnosis of latent yaws was ulcers negative for T pertenue. 
Asymptomatic individuals (no suspicious skin lesions) 
from randomly selected villages who were assessed and 
enrolled during baseline serosurveys of the eradication 
programme were also included.
We classified participants with dual positivity on TPHA 
and RPR into three groups, on the basis of PCR testing: 
group 1 included asymptomatic people with no ulcers and 
who were not tested with PCR; group 2 included people 
with ulcers negative for T pertenue on PCR; and group 3 
included people with an ulcer and PCR evidence of active 
yaws. Groups 1 and 2 constituted the latent yaws study 
population and group 3 was the active yaws comparator 
group. The Medical Research Advisory Committee of 
Papua New Guinea approved the study protocol 
(number 12.36). All eligible people were in formed of the 
study’s aims, procedures, and associated risks and provided 
informed consent (children <15 years gave verbal consent 
and their parents or guardians provided written consent).
Procedures
All participants with skin ulcers underwent clinical, 
serological, and PCR assessments, were treated with one 
directly observed oral dose of 30 mg/kg azithromycin, 
and were followed up in village community outreach 
clinics for repeated RPR testing at 6, 12, and 24 months. 
Follow-up was discontinued when results showed 
serological cure. Asymptomatic participants also received 
one oral dose of 30 mg/kg azithromycin and were 
followed up at 12 and 24 months.
The serological reactivity was determined at the Lihir 
Medical Centre laboratory by RPR and TPHA testing 
(both Human Diagnostics Worldwide, Wiesbaden, 
Germany). To calculate RPR titre, a blood serum sample 
was diluted in serial ratios until there was no longer 
antibody reactivity. Real-time (rt)PCR specific for 
T pertenue and H ducreyi was done on all lesional swab 
samples at the University of Washington laboratory, 
Seattle, WA, USA. Three primer sets for three independent 
T pallidum gene targets—tp0548, tpN47 (also known as 
Research in context
Evidence before this study
We searched PubMed, without language restrictions, for studies 
of the efficacy of single-dose oral azithromycin to treat latent 
treponemal disease published up to April 1, 2017, with the search 
terms “yaws”, “syphilis”, “latent”, and “azithromycin”. 
We identified four studies showing that azithromycin was 
efficacious in treating early latent syphilis in several regions 
(North America, Madagascar, Tanzania, and Taiwan). 
Additionally, studies in Congo, Ghana, Papua New Guinea, 
the Solomon Islands, and Vanuatu indicated that 
community-level prevalence of latent yaws fell substantially after 
mass treatment with azithromycin. In those studies, however, 
different samples of children were selected for each round of 
cross-sectional surveys, meaning that no study followed up a 
consistent group of participants. We did not identify any study 
that used serological monitoring to assess individual response to 
treatment of latent yaws with azithromycin.
Added value of this study
In the context of a pilot yaws eradication programme, we 
investigated the serological response to treatment in a large 
cohort of people with latent yaws confirmed by serology and PCR. 
The use of PCR enabled clear differentiation between active and 
latent yaws, which represents a strong advance over the methods 
used in previous studies. We followed up the same study cohort 
for 24 months, which meant that we could reliably determine 
whether serological titres declined to the expected extent after 
treatment, including in participants in whom decline was slow.
Implications of all the available evidence
We found that one dose of 30 mg/kg oral azithromycin led to 
serological cure in a high proportion of participants with latent 
yaws. When taken together with the previous findings on 
treatment of latent syphilis, the data suggest efficacy of 
azithromycin to treat latent treponematoses, including yaws. 
Studies done in the 1950s showed that, owing to the tendency of 
latent yaws to relapse early in the course of untreated infection, 
treatment of latent disease is a crucial part of eradication efforts. 
Our findings, therefore, support the WHO strategy of mass 
administration of azithromycin irrespective of clinical status, 
which allows people harbouring the infection without any skin 
manifestations (ie, latent infection) to be exposed to treatment. 
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tp0574), and a pertenue-specific region of tprL (also known 
as tp1031)—were PCR amplified to detect the presence of 
T pallidum DNA and to confirm the subspecies, as has 
been described previously.3 We used Taqman rtPCR 
targeting the 16S rRNA gene to identify H ducreyi.13
Definitions
The primary endpoint of the study was serological cure at 
24 months, defined as a decrease in the RPR titre by at 
least two dilutions (fourfold) at any time during the 
study (eg, change from 1:16 at baseline to 1:4).14 Participants 
not cured at 24 months were classified either as having 
treatment failure, defined as at least two dilutions (fourfold) 
increase in RPR titre (eg, change from 1:16 at baseline to 
1:64), or having non-significant change, defined as either 
no change in titre or a decrease or increase of one dilution 
(twofold) from baseline (eg, change from 1:16 at baseline to 
either 1:8 or 1:32), based on the 24-month RPR titre. The 
outcome categories were mutually exclusive. The 
secondary endpoint was the proportion of participants 
with seroreversion to non-reactive at 24 months (ie, no 
anti bodies detectable by RPR testing).
Statistical analyses
We calculated that a sample size of 165 participants in 
the latent yaws group and 108 in the active yaws 
comparator group (sampling ratio 1·5) would give a 
power of 98% to test the hypothesis of non-inferiority.15 
This sample size accounted for an expected efficacy of 
91∙5% in the latent yaws group and of 93·5% in the 
active yaws group, a non-inferiority margin of 10%, and 
a one-sided type I error rate of 0∙05.
We included in the primary analysis participants who 
were treated and completed the study procedures for 
outcome assessment at 24 months. Data on participants 
who were lost to follow-up before serological cure were 
censored at the time of the last follow-up visit and were 
not included in the primary analysis.
To analyse the primary endpoint, we estimated the 
two-sided 95% CIs for the difference in proportions of 
parti cipants with serological cure by subtracting the 
active yaws group values from the latent yaws group 
values. Treatment of latent yaws was deemed to be non-
inferior to that of active yaws if the lower bound of the 
CI was higher than or equal to –10%. We used the same 
method to analyse the secondary endpoint. We did 
subgroup analyses to investigate the association 
between serological cure and time of retesting by use of 
differences in proportions or mean baseline RPR titre, 
assessed with the Student’s t test of geometric means 
with serum RPR titre as a continuous variable. We 
did all statistical analyses with Stata version 14.1. This 
483 participants in group 2
(latent yaws, ulcers TP 
negative on PCR) treated 
with azithromycin
 
1155 people assessed for eligibility
 
105 participants TPHA positive 
and RPR ≥1:8 enrolled for 
follow-up to monitor 
serology
 
378 excluded
179 TPHA negative, RPR <1:8
198 TPHA positive, RPR <1:8
1 TPHA negative, RPR ≥ 1:8
3 lost to follow-up after enrolment
10 censored (lost to follow-up 
      before cure) 
3 re-treated for yaws due to 
   recurrent skin ulcer
24 months 
83 serological cure 
3 serological failure
3 non-significant change
 
188 participants in group 3 
(active yaws, ulcers TP positive 
on PCR) treated with 
azithromycin
 
121 participants TPHA positive and 
RPR ≥1:8 enrolled for follow-up 
to monitor serology
67 excluded
27 TPHA negative, RPR <1:8
38 TPHA positive, RPR <1:8
2 TPHA negative, RPR ≥1:8
2 lost to follow-up after enrolment
9 censored (lost to follow-up 
    before cure)
2 re-treated for yaws due to 
    recurrent skin ulcer
24 months 
101 serological cure 
1 serological failure
6 non-significant change
484 participants in group 1 
(asymptomatic, without 
ulcers) treated with 
azithromycin
 
85 participants TPHA positive 
and RPR ≥1:8 enrolled for 
follow-up to monitor serology
 
399 excluded
219 TPHA negative, RPR <1:8
168 TPHA positive, RPR <1:8
12 TPHA negative, RPR ≥1:8
 
7 lost to follow-up after enrolment
2 censored (lost to follow-up 
    before cure) 
 
24 months 
68 serological cure  
8 non-significant change
 
Figure 1: Study profile
TP=Treponema pallidum subsp pertenue. TPHA=T pallidum haemagglutination assay. RPR=rapid plasma reagin.
Articles
e1271 www.thelancet.com/lancetgh   Vol 5  December 2017
study is registered with ClinicalTrials.gov, number 
NCT01955252.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Of 1155 individuals assessed for eligibility, 484 were 
asymptomatic (group 1), 483 had skin ulcers negative for 
T pertenue on rtPCR (group 2), and 188 had skin ulcers 
positive for T pertenue on rtPCR (group 3). Among these, 
311 children had a reactive TPHA and an RPR titre of at 
least 1:8, all of whom were enrolled in the study (figure 1). 
The mean age of participants was 10·1 years (SD 5·7), 
178 (57%) were boys and 133 (43%) were girls. The numbers 
of patients who had baseline RPR titres of at least 1:16 or at 
least 1:64 in the latent yaws group did not differ significantly 
from those in the active yaws group (table 1).
12 (4%) of 311 participants enrolled could not be traced 
for any follow-up visit, 21 (7%) were censored at 6 or 
12 months, and five (2%) were excluded after being re-
treated for presumed symptomatic reinfection or relapse 
(figure 1). Therefore, 273 participants were included in 
the analyses of serological cure at 24 months. 252 patients 
were classified as having serological cure and 21 as 
having treatment failure or non-significant change 
outcomes at 24 months.
The risk difference for serological cure between the 
latent versus the active yaws groups met the prespecified 
criteria for non-inferiority (table 2). In the sensitivity 
analysis of participants who were tested three times (ie, 
excluding group 1), non-inferiority was maintained 
(83 [93%] vs 101 [94%], risk diff erence –0·3%, 95% CI 
–7·2 to 6·7). Additionally, the proportions of participants 
with serological cure at 24 months were similar in 
groups 1 and 2 (68 [90%] vs 83 [93%], p=0·383), 
which supports the adequacy of combining asymptomatic 
and PCR-negative participants in the latent group. 
14 participants with latent yaws did not achieve serological 
cure (table 3). Three or four dilution decreases in RPR 
titre were seen frequently in both the latent yaws and 
active yaws groups (table 3). The proportion of participants 
with seroreversion was significantly lower in the latent 
yaws group than in the active yaws group (table 2).
We did a post-hoc analysis of individuals with baseline 
RPR titres of 1:2 or 1:4 in groups 2 (n=54) and 3 (n=21), 
who were excluded from the main analysis. In group 2, 
28 (52%) participants achieved a two-dilution decrease in 
RPR titre or seroreversion at 24 months, compared with 
15 (71%) in group 3 (risk difference –19·6%, 95% CI 
–43·0 to 3·9). Some indi viduals with baseline RPR titres 
of 1:2 or 1:4 who had persistently unchanged RPR titres at 
24 months were probably actually serofast, which 
supports the appropriateness of excluding this group of 
patients from our analysis.
At retesting visits, the latent yaws group included only 
group 2 participants at 6 months, but group 1 and 2 parti-
cipants at 12 months. The proportions with serological 
cure did not differ significantly between the latent and 
active yaws groups in the subgroup analysis of time of 
retesting, either at 6 months (58 [83%] vs 59 [88%], risk 
difference –5·2%, 95% CI –17·0 to 6·6) or at 12 months 
(125 [86%] vs 74  [90%], –4·0%, –12·6 to 4·5; figure 2A). 
The proportion of participants with sero reversion was 
lower in the latent yaws group than in the active yaws 
group at 6 months (12 [17%] vs 30 [45%]; risk 
difference –27·6%, 95% CI –42·4 to –12·8) and 12 months 
(47 [32%] vs 44 [54%], –21·2%, –34·5 to–8·0; figure 2C).
Mean baseline RPR titre was 40·1 (SD 43·3) in 
participants with serological cure, compared with 
34·9 (24·0) in participants who did not achieve serological 
cure (p=0·721). We saw no difference in serological 
response at 24 months between participants with latent or 
active yaws by baseline RPR titre (figure 2B). The mean 
baseline RPR titre was 33·3 (SD 35·4) in participants 
Latent yaws (n=190)* Active yaws (n=121)† p value
Age (years) 10·4 (5·4) 9·8 (6·0) 0·361
Boys 101 (53%) 77 (64%) 0·069
Girls 89 (47%) 44 (36%) ··
RPR titre
≥1:16 160 (84%) 92 (76%) 0·076
≥1:64 75 (40%) 42 (35%) 0·395
Data are mean (SD) or number (%). RPR=rapid plasma reagin. *Defined as ulcers 
negative for Treponema pallidum subsp pertenue on PCR or no suspicious skin 
lesions. †Defined as ulcers positive for T pertenue on PCR.
Table 1: Baseline characteristics of the study population
Latent yaws infection 
(n=165)*
Active yaws infection 
(n=108)†
Absolute difference in 
risk (95% CI)
Serological cure‡ 151 (92%) 101 (94%) –2·0% (–8·3 to 4·3)
Seroreversion§ 73 (44%) 63 (58%) –14·1% (–26·1 to –2·1)
RPR=rapid plasma reagin. *Defined as ulcers negative for Treponema pallidum subsp pertenue on PCR or no suspicious 
skin lesions. †Defined as ulcers positive for T pertenue on PCR. ‡Decrease in RPR titre by two or more dilutions. 
§RPR reverted to non-reactive. 
Table 2: Serological cure or seroreversion 24 months after treatment with azithromycin
Number of 
patients
Treatment 
failure*
Non-significant 
change†
Number of dilution reductions in RPR 
titre
Two Three Four
Latent yaws 165 3 (2%) 11 (7%) 14 (9%) 29 (18%) 108 (66%)
Active yaws 108 1 (1%) 6 (6%) 14 (13%) 30 (28%) 57 (53%)
RPR=rapid plasma reagin. *At least two dilutions increase in RPR titre. †No change or one dilution (twofold) reduction 
or increase in RPR titre.
Table 3: Outcomes 24 months after treatment with azithromycin, by clinical stage
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with seroreversion compared with 43·8 (SD 43·8) in 
participants without seroreversion (p=0·034). The pro-
portion of participants with seroreversion at 24 months 
was lower among those with latent yaws than among 
those with active yaws by RPR titre at baseline (figure 2D).
Discussion
The primary endpoint of serological cure at 24 months 
was seen in 92% of patients with latent yaws after 
treatment with single-dose azithromycin, which was 
similar to that among participants with rtPCR-confirmed 
active yaws. These results expand on the data showing 
efficacy with 30 mg/kg single-dose azithromycin for 
treatment of early syphilis, including in the early latent 
stage.16–19 Before this study, mass treatment with azithro-
mycin had been shown to reduce the prevalence of latent 
yaws significantly at the community level.5,9–12 People with 
latent yaws, however, had not been consistently and 
prospectively followed up over a long period of time to 
mon itor serological cure at the individual level.
The RPR titre data indicate that successful treatment for 
active and latent yaws often results in three or four dilution 
decreases, but seroreversion was seen with this non-
treponemal test in less than 50% of participants with latent 
yaws. As reported for syphilis,14 participants with high 
baseline titres in this study had greater declines than did 
those with lower titres at base line, but were less likely to 
have seroreversion. We stress that non-treponemal tests 
can show reactivity at low titres in a high percentage of 
people, even a long time after treatment, and, therefore, do 
not necessarily indicate untreated yaws. Similar persistent 
reactivity at low titres is seen after treatment of syphilis 
with azithromycin or benzathine benzyl penicillin, and is 
referred to as serofast status. This evidence supports the 
inclusion of sero surveys in yaws eradication pro grammes 
to assess inter ruption of yaws transmission at least 
24 months after mass treatment, alone or with the use of 
an RPR titre cutoff below which further testing is needed 
before serology is classified as positive.
Our study has several limitations. First, the RPR test is 
read by naked eye and there is a degree of inter-observer 
variability in inter pretation of test results that can lead to 
variation in RPR titre of plus or minus one dilution.20 We 
attempted to minimise variation by having all RPR 
testing done by one technician at a central laboratory 
with simultaneous retesting of serum samples taken 
before and after treatment and stored frozen. Second, 
because of the observational nature of our study design, 
there was no untreated control group. As the duration 
of untreated syphilis increases, titres might decline by 
two or more dilutions.21,22 A similar effect could have 
contributed to the results for yaws in our study. Add-
itionally, there was no control group of participants 
treated with benzathine benzylpenicillin. We did, 
however, include a comparator group of children with 
active yaws infection, and a study of single-dose 
azithromycin compared with benzathine benzylpenicillin 
for active yaws showed non-inferiority.6 Third, by 
excluding people with baseline RPR titres of 1:2 or 1:4, 
the latent sample might be biased in favour of early latent 
infection or people between the primary and secondary 
stages. Serological cure at 24 months was seen in only 
52% of participants with low-titre RPR latent yaws, which 
might reflect stable non-treponemal antibody titres in 
the serofast state. However, we cannot rule out that the 
lower serological cure exhibited was related to infections 
later in the natural history. This pattern, though, would 
not affect the WHO yaws eradication programmes 
because late latent yaws, in which lesions are not present, 
is not an important contributor to incident infections, 
but it would have implications for individuals’ health and 
clinical management. Finally, group 1 had a different 
follow-up schedule from groups 2 and 3 (two vs 
three occasions for testing) and, therefore, serological 
cure might have been under estimated in group 1. 
Although this difference could bias the non-inferior 
result towards inferiority for treatment of latent yaws, we 
were still able to show non-inferiority. Furthermore, non-
inferiority was maintained in a sensitivity analysis of 
only groups 2 and 3. Of note, in people with latent yaws 
(or syphilis) it can take 12–24 months for the full 
amplitude of RPR titre fall to be expressed after successful 
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Figure 2: Serological cure or seroreversion by infection status
Serological cure (decrease in RPR titre by two or more dilutions) was determined as a function of (A) time of 
retesting after treatment and (B) baseline RPR titre. Seroreversion (RPR reverted to non-reactive) was determined as 
a function of (C) time of retesting after treatment and (D) baseline RPR titre. We report proportions of patients with 
latent or active yaws with serological cure at 6, 12, and 24 months. Asymptomatic participants were not followed 
up at 6 months and, therefore, data are included in the latent yaws group at 12 and 24 months only. RPR=rapid 
plasma reagin. 
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treatment and, therefore, serology at 12 and 24 months is 
more reliable than assessment at 6 months, which 
group 1 missed.
In common with other yaws-endemic regions studied, 
we found that a substantial proportion of skin lesions 
clinically attributed to yaws contained H ducreyi DNA.4 
Isolates of H ducreyi obtained from skin lesions of children 
in Vanuatu and Samoa were sensitive to azithromycin in 
vitro,23 and the antibiotic is recommended for the treat-
ment of sexually transmitted H ducreyi infections.24 On 
Lihir Island, 2 weeks after treatment with azithromycin, 
around 90% of all ulcers containing H ducreyi were totally 
re-epithelialised or greatly improved.25 Hence, azithro-
mycin has the double effect of treating H ducreyi ulcers 
and latent yaws.
Failure of targeted treatment of people with active yaws 
and their contacts with penicillin by WHO and UNICEF 
in the 1940s and 1950s was thought to be due to continued 
untreated asymptomatic infection because of the 
tendency for untreated latent yaws to relapse early.26,27 
Treatment of latent disease is, therefore, a crucial part of 
eradication efforts. The availability of a well tolerated oral 
agent prompted WHO to develop an eradication strategy 
that involved treatment of all members of yaws-endemic 
communities, irrespective of clinical status. Our findings 
provide clear evidence that one high dose of azithromycin 
is effective for treatment of latent yaws, and support 
WHO’s strategy for yaws eradication. However, a study 
done on Lihir Island showed that one round of mass 
treatment might be insufficient because of relapse of 
latent yaws in people who were absent at the time of 
treatment (unpublished). Our results showing the 
effectiveness of single-dose azithromycin for treating 
latent yaws support relapse from untreated latent yaws, 
rather than from azithromycin treatment failure, playing 
a part in persistent transmission of the disease. More 
than one round of treatment would increase the likelihood 
of treating each person at least once.
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